Adaptin Bio (APTN) Total Current Liabilities (2022 - 2026)

Adaptin Bio has disclosed Total Current Liabilities across 5 years of filings, most recently posting $2.6 million for Q2 2026.

• In Q2 2026, Total Current Liabilities rose 122.75% year-over-year to $2.6 million; the TTM figure through Jun 2026 stood at $2.6 million (up 122.75% YoY), while the FY2025 annual figure was $2.1 million, down 51.41% from the prior year.
• Total Current Liabilities came in at $2.6 million for Q2 2026 at Adaptin Bio, up from $2.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $4.3 million in Q4 2024 to a low of $27804.0 in Q4 2022.
• Average Total Current Liabilities over 5 years is $1.3 million, with a median of $1.1 million recorded in 2025.
• Year-over-year, Total Current Liabilities surged 3730.9% in 2024 and slumped 51.41% in 2025.
• Over 5 years, Total Current Liabilities stood at $27804.0 in 2022, then jumped by 307.41% to $113277.0 in 2023, then surged by 3730.9% to $4.3 million in 2024, then tumbled by 51.41% to $2.1 million in 2025, then advanced by 25.53% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $2.6 million in Q2 2026, $2.5 million in Q1 2026, and $2.1 million in Q4 2025.